A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors

NCT06524804 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor adjusts the clinical development strategy.

Conditions

Solid Tumor, Adult

Interventions

DRUG: BY101298 Capsules
RADIATION: palliative radiotherapy
DRUG: BY101298 Capsules
RADIATION: curative radiotherapy

Sponsor

Chengdu Baiyu Pharmaceutical Co., Ltd.